全球软糖格式膳食补充剂研发商TopGum完成对PL Developments在美国软糖生产业务的收购-动脉网

TopGum Completes U.S. Acquisition of PL Developments Valued at Up to USD 35 Million

PR Newswire 等信源发布 2026-05-05 18:59



可切换为仅中文







TopGum deepens U.S. market presence, enters the pharmaceutical space and launches a long-term strategic commercial partnership with PL Developments

TopGum深化美国市场存在，进入制药领域，并与PL Developments展开长期战略性商业合作。

The transaction positions TopGum as a pioneer in the emerging pharmaceutical gummies market

该交易使TopGum成为新兴制药软糖市场的先驱。

RAMAT GAN, Israel and COPIAGUE, New York

以色列拉马特甘和纽约科皮阿格

，

May 5, 2026

2026年5月5日

/PRNewswire/ -- TopGum Industries Ltd. (TASE: TPGM), a global leader in gummy-format dietary supplements, and P&L Developments LLC ('PLD'), a leading U.S. OTC pharmaceuticals company developing and manufacturing healthcare products, today announced the completion of TopGum's acquisition of PLD's U.S.

/PRNewswire/ -- 全球领先的软糖形式膳食补充剂企业TopGum Industries Ltd.（特拉维夫证券交易所代码：TPGM），与美国领先的非处方药公司P&L Developments LLC（“PLD”）今日宣布，TopGum已完成对PLD美国业务的收购。

gummy manufacturing operations. The transaction, first announced via a binding letter of intent on January 20, 2026, deepens TopGum's presence in the United States, its largest target market, and positions TopGum as a pioneer in the emerging pharmaceutical gummies market. TopGum and PLD agreed to launch a strategic commercial partnership under which PLD will commercialize and distribute TopGum-manufactured products to leading U.S.

软糖制造业务。该交易于2026年1月20日通过一份具有约束力的意向书首次宣布，加深了TopGum在美国这一其最大目标市场的影响力，并使TopGum成为新兴药品软糖市场的先驱。TopGum和PLD同意启动一项战略性商业合作伙伴关系，根据该合作，PLD将把TopGum生产的产品商业化并分销给美国的主要企业。

retailers under store-brand labels..

零售商使用商店品牌标签。

继续阅读

TopGum Completes U.S. Acquisition of PL Developments Valued at Up to USD 35 Million

TopGum完成对PL Developments的美国收购，价值高达3500万美元

The completion of the transaction reinforces TopGum's position as a leading innovative company in its field and marks a significant milestone in its strategy to become a leading global player in healthcare products built on advanced, enjoyable delivery systems.

该交易的完成巩固了TopGum作为其领域内领先的创新公司的地位，并标志着其成为基于先进且愉悦的递送系统构建的全球领先医疗保健产品公司的战略中一个重要的里程碑。

The acquisition gives TopGum a U.S.-based manufacturing platform purpose-built to FDA pharmaceutical standards, capable of producing both pharmaceutical gummies and dietary supplements. This state-of-the-art facility is among a select few globally to have reached operational manufacturing capability for pharmaceutical gummies..

此次收购使TopGum获得了一个基于美国的制造平台，该平台专为符合FDA制药标准而设计，能够生产制药软糖和膳食补充剂。这座最先进的设施属于全球少数几家已达到制药软糖生产能力的工厂之一。

Strategic Rationale

战略理由

The combination of TopGum and PLD's gummy operations addresses two major structural shifts in the U.S. consumer health market: the accelerating migration of both VMS and pharmaceutical products into gummy and other enjoyable dosage forms and the rising retailer and brand demand for U.S.-based supply chains.

TopGum与PLD的软糖业务相结合，应对了美国消费者健康市场的两大结构性变化：维生素、矿物质和补充剂（VMS）以及药品加速向软糖和其他受欢迎的剂型转变，以及零售商和品牌对美国本土供应链需求的不断增长。

TopGum estimates that the pharmaceutical gummy market is expected to follow a similar accelerated growth trajectory to the one experienced by the dietary supplements market over the past 15 years, during which the gummy format became the leading dosage form..

TopGum 估计，制药软糖市场预计会遵循与过去 15 年膳食补充剂市场所经历的类似的加速增长轨迹，在此期间，软糖形式成为了领先的剂量形式。

For TopGum, the transaction:

对于TopGum，该交易：

Strengthens TopGum's position as a leading innovative company and establishes it as a pioneer in the pharmaceutical gummy space.

加强了TopGum作为领先的创新公司的地位，并使其成为制药软糖领域的先锋。

Establishes a U.S. manufacturing presence for the first time, shortening lead times and bringing the company closer to its largest customer base.

首次在美国建立制造基地，缩短交货时间，并使公司更接近其最大的客户群。

Creates meaningful expansion headroom - the facility's existing infrastructure supports more than a doubling of production capacity through additional lines, without significant incremental capital investment.

创造了有意义的扩展空间——设施的现有基础设施通过增加生产线，无需显著的增量资本投资，即可支持生产容量翻倍以上。

Creates a global, state-of-the-art manufacturing platform across Israel, Canada, and the United States – enabling TopGum to meet the needs of leading U.S. VMS, healthcare and retail partners.

在以色列、加拿大和美国创建了一个全球领先的制造平台——使TopGum能够满足美国主要VMS、医疗保健和零售合作伙伴的需求。

For PLD, the transaction:

对于PLD，交易：

Redeploys a specialized manufacturing asset to a category-dedicated operator, while preserving and expanding PLD's ability to bring high quality gummy products to its customers.

将专用制造资产重新部署给专注于某一类别的运营商，同时保留并扩大小PLD为客户提供高品质软糖产品的能力。

Secures privileged access to TopGum's global portfolio and development pipeline for PLD's U.S. partners.

确保PLD的美国合作伙伴获得TopGum全球产品组合和开发管道的特权访问。

Enables PLD to serve accelerating retailer demand for gummy formats, across VMS and drug categories.

使PLD能够满足零售商对软糖形式日益增长的需求，涵盖VMS和药品类别。

Commercial Partnership

商业伙伴关系

In parallel with the acquisition, TopGum and PLD have entered into a long-term strategic partnership for the commercialization of TopGum's dietary supplement and pharmaceutical gummy portfolio to leading U.S. retailers under store-brand labels. PLD will leverage its established retail relationships and packaging operations to bring TopGum-manufactured products to market..

在收购的同时，TopGum 和 PLD 已经建立了一个长期战略合作伙伴关系，将 TopGum 的膳食补充剂和制药橡皮糖产品组合以商店品牌标签的形式推广给美国主要零售商。PLD 将利用其已建立的零售关系和包装业务，将 TopGum 生产的产品推向市场。

— Eyal Shohat, Chief Executive Officer, TopGum, commented:

——托普胶姆首席执行官艾亚尔·肖哈特评论道：

'This is a strategic transaction that gives TopGum a unique foothold in the emerging pharmaceutical gummy market and reinforces its positioning as an innovative, leading company in its field. The transaction positions TopGum as a unique player with an advanced global manufacturing platform, built to serve the largest dietary supplement brands in the U.S.

“这是一次战略性的交易，使TopGum在新兴的制药软糖市场中占据了独特的立足点，并巩固了其作为领域内创新领导者的地位。此次交易使TopGum成为一家拥有先进全球制造平台的独特参与者，旨在为美国最大的膳食补充剂品牌提供服务。

with local manufacturing. Partnering with PLD, one of the leading generic pharmaceutical companies in the U.S., gives us access to leading U.S. retail chains and accelerates our growth in this market. The fact that a significant portion of the consideration is contingent and share-based reflects PLD's confidence in TopGum's strategy, capabilities and long-term growth trajectory.

通过本地制造合作。与美国领先的仿制药公司之一PLD合作，使我们能够进入美国主要零售连锁店，并加速我们在这一市场的增长。相当一部分对价是基于股权和或有条件支付，这反映了PLD对TopGum的战略、能力以及长期增长轨迹的信心。

The pharmaceutical gummy category is in its earliest innings, and we believe it will follow the same arc the dietary supplement market followed over the past 15 years, when the gummy format became the dominant one. We view the completion of the transaction as a significant milestone in TopGum's growth trajectory, and we are at the beginning of a new chapter in the Company's accelerated expansion as we continue our journey to become a leading player in healthcare products built on enjoyable, advanced delivery systems.'.

制药软糖类别尚处于发展的初期阶段，我们认为它将遵循与过去15年膳食补充剂市场相同的轨迹，当时软糖形式成为了主导。我们视此次交易的完成为TopGum增长历程中的重要里程碑，随着我们继续致力于成为基于愉悦、先进传输系统的医疗保健产品领先者，公司正迎来加速扩张的新篇章。

— Evan Singer, President, P&L Development, commented:

— P&L Development 总裁 Evan Singer 评论道：

'At PLD, we see gummies as an emerging platform for delivering healthcare across vitamins, minerals and supplements (VMS) and pharmaceutical products, which customers and consumers are increasingly asking for. This transaction gives us the ability to serve that demand at an even more aggressive speed and scale, by partnering with a world-class gummy manufacturing & development company.

“在PLD，我们将软糖视为一种新兴的医疗保健平台，用于传递维生素、矿物质和补充剂（VMS）以及医药产品，这是客户和消费者日益增长的需求。通过与一家世界级的软糖制造和开发公司合作，此次交易使我们能够以更快速度和更大规模满足这一需求。”

The deal structure itself is creative and delivers on two priorities at once: putting a purpose-built, FDA-compliant gummy manufacturing platform into the hands of a global category leader who will scale it, while securing PLD privileged access to TopGum's portfolio and development pipeline for our U.S.

交易结构本身富有创意，同时实现了两个优先事项：将一个专门为全球品类领导者打造的、符合FDA标准的软糖生产平台交到能够扩大其规模的领导者手中，同时确保PLD优先获得TopGum的产品组合和开发管道，以服务于我们的美国市场。

customers. We expect to be bringing TopGum products to our retail partners in the coming months.'.

客户。我们预计将在未来几个月内将TopGum产品带给我们的零售合作伙伴。

Pipeline and Regulatory Pathway

管道和监管途径

The acquired operation has a development pipeline spanning both dietary supplements and pharmaceutical gummies, with several products nearing commercial launch. In partnership with one of the world's largest pharmaceutical companies - which is funding the development work - the operation is also advancing products under the OTC monograph framework and the FDA's 505(b)(2) pathway, which enables approval of new dosage forms of existing drugs and provides a minimum of three years of marketing exclusivity.

收购的业务拥有涵盖膳食补充剂和制药软糖的发展管道，多种产品即将实现商业化推出。该业务与世界上最大的制药公司之一合作（后者正在资助开发工作），还在非处方药专论框架以及FDA的505(b)(2)途径下推进产品，这使得现有药物的新剂型能够获得批准，并提供至少三年的市场独占期。

These pharmaceutical gummy products are currently targeted to launch in 2027 and 2028 under the partner's brands, with TopGum serving as exclusive manufacturer..

这些制药软糖产品目前计划于2027年和2028年在合作伙伴的品牌下推出，TopGum将作为独家制造商。

TopGum is also evaluating certification of the facility under additional regulatory regimes, including Australia's Therapeutic Goods Administration (TGA), which would open access to Australian and adjacent markets.

TopGum 还在评估该设施在其他监管制度下的认证，包括澳大利亚治疗用品管理局 (TGA)，这将打开通往澳大利亚及周边市场的通道。

Transaction Terms

交易条款

The consideration, funded by TopGum's existing resources, comprises:

由TopGum现有资源资助的对价包括：

US$ 10 million in cash

1000万美元现金

at closing

在收盘时

1,893,060 shares

1,893,060股

valued at approximately US$ 8 million at closing (based on a price of NIS 13 per share)

在收盘时估值约为 800 万美元（基于每股 13 新谢克尔的价格）

Up to 4,022,751 additional shares

最多4,022,751股额外股份

(valued at up to US$ 17 million) as contingent consideration, payable upon achievement of agreed commercial and regulatory milestones

（价值高达1700万美元）作为或有对价，将在达成约定的商业和监管里程碑时支付。

On a fully diluted basis, assuming achievement of all milestones, P&L Development will become a major shareholder of TopGum, holding approximately 4% of the company's equity.

在完全稀释的基础上，假设所有里程碑都达成，P&L Development将成为TopGum的主要股东，持有公司约4%的股权。

TopGum has also agreed to act for the appointment of Asaph Naaman, Chief Financial Officer of PL Developments to its Board of Directors, subject to applicable law and required approvals.

TopGum 还同意根据适用法律和所需批准，任命 PL Developments 的首席财务官阿萨夫·纳曼为其董事会成员。

TopGum 2026 Outlook

顶峰口香糖2026展望

TopGum expects 2026 to be a transition year focused on integrating the acquired operation into its North American platform. Revenue from the acquired operation is expected to be in the low single-digit millions in 2026, with a negative EBITDA contribution of approximately $2 to $3 million — typical of an integration year — with the operation expected to generate its full earnings power in subsequent years..

TopGum预计2026年将是过渡年，重点将收购的业务整合到其北美平台。收购业务在2026年的收入预计将达到数百万美元的低位数，EBITDA贡献为负的约200万至300万美元——这是整合年份的典型情况——预计该业务将在随后几年实现其全部盈利潜力。

The acquisition was completed during a period of accelerated growth for TopGum. The company reached an annualized revenue run-rate of approximately $120 million in the second half of 2025, supported by the completion of the Island Abbey acquisition in Canada in early 2025, the November 2025 commercial commissioning of TopGum's new manufacturing facility in Sderot, Israel, and a series of strategic supply agreements with leading customers in North America.

TopGum 在快速增长的时期完成了此次收购。公司在 2025 年下半年实现了约 1.2 亿美元的年化收入运行率，这得益于 2025 年初在加拿大完成的 Island Abbey 收购、2025 年 11 月 TopGum 位于以色列斯德罗特的新制造工厂的商业投产，以及与北美主要客户达成的一系列战略供应协议。

With this transaction, TopGum's global manufacturing footprint now spans Israel, Canada, and the United States..

通过此次交易，TopGum 的全球制造业务现已覆盖以色列、加拿大和美国。

About TopGum

关于TopGum

Founded in 2004, TopGum is a global leader in the manufacturing of dietary supplements in gummy dosage form, with products sold worldwide. The company's manufacturing facilities are located in Israel, Canada, and - following the completion of this transaction - the United States. TopGum employs more than 400 people and is listed on the Tel Aviv Stock Exchange.

TopGum 成立于2004年，是全球领先的软糖剂型膳食补充剂制造商，产品销往世界各地。公司生产设施位于以色列、加拿大，并且在本次交易完成后也将位于美国。TopGum 拥有400多名员工，并在特拉维夫证券交易所上市。

Its principal shareholders include founder and President Hai Hayon, Roi Lusternik, and institutional investors. Raviv Zoller serves as Chairman, having assumed the role in January 2026. Eyal Shohat is Chief Executive Officer..

其主要股东包括创始人兼总裁海·哈永、罗伊·卢斯蒂尼克和机构投资者。拉维夫·佐勒自2026年1月起担任董事长，埃亚尔·肖哈特为首席执行官。

About P&L Development

关于P&L发展

PL Developments is a family-owned U.S. pharmaceutical and consumer healthcare contract development and manufacturing organization (CDMO) headquartered in Westbury, New York and Miami, Florida. PLD develops, manufactures, packages, and distributes more than 450 products across over 2,000 SKUs for leading U.S.

PL Developments是一家家族所有的美国制药和消费者健康护理合同开发和制造组织（CDMO），总部位于纽约州韦斯特伯里和佛罗里达州迈阿密。PLD为美国领先的公司开发、制造、包装和分销超过450种产品，涵盖2000多个SKU。

retailers and global brand partners, operating from FDA-registered facilities in Westbury, New York; Doral, Florida; Greenville, South Carolina; and Los Angeles, California. With more than 1,500 associates across more than 2 million square feet of U.S.-domiciled pharmaceutical manufacturing, packaging, and distribution facilities, PLD is a trusted CDMO partner to every major U.S.

零售商和全球品牌合作伙伴，从纽约州韦斯特伯里、佛罗里达州多拉尔、南卡罗来纳州格林维尔和加利福尼亚州洛杉矶的FDA注册设施运营。PLD拥有超过1,500名员工，分布在美国境内超过200万平方英尺的制药生产、包装和分销设施中，是美国各大主要企业的值得信赖的CDMO合作伙伴。

retail chain offering store-brand consumer healthcare products and to many of the world's largest consumer healthcare companies..

提供商店品牌消费者健康产品的零售连锁店，以及世界上许多最大的消费者健康公司。

For more information, contact:

欲了解更多信息，请联系：

Company contact:

公司联系人：

TopGum Industries, Ltd.

顶胶工业有限公司

Inbal Nahmias

因巴尔·纳赫米亚斯

Head of Global Marketing and Sustainability